Indonesia: digestive and intestinal remedies market revenue 2027

In 2022, the digestive and intestinal remedy market in Indonesia generated a revenue of around 298 million U.S. dollars. The Statista Health Market Outlook estimated the revenue of the market would continue to increase and reach around 362.4 million U.S. dollars by 2027.

Revenue of the digestive and intestinal remedies market in Indonesia from 2018 to 2027 (in million U.S. dollars)

Characteristic	Revenue in million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

The Digestives and Intestinal Remedies market comprises over-the-counter natural and synthetic digestive agents and remedies against gastrointestinal complaints. Digestives include preparations in the form of pills, powder, capsules, liquids, solutions, suspensions, drops and suppositories. Not included are prescription medicines, preparations that are against the state law or are not explicit digestive drugs (e.g. painkillers). Among the top-selling digestives are Perenterol, Iberogast, Dulcolax and Buscopan Plus. It includes both products which are exclusively sold in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

A detailed methodology can be found in the Statista Market Outlook.

Citation formats